Entomology Technician
About the job
- Strong oral and written communication skills.
- Strong organizational skills and the ability to work in a dynamic laboratory environment.
- Ability to work independently and drive projects to completion.
- Ability to partner successfully with team members and stakeholders from a variety of backgrounds.
- Conduct laboratory bioassays, including setup, implementation, and assessment.
- Coordinate and schedule laboratory resources to maintain an efficient screening process.
- Work with team members to develop and improve bioassays.
- Collect and manage data and perform quality assurance.
- Follow laboratory safety practices to ensure a safe work environment.
- Ensure the quality of bioassays and the accuracy of generated data.
- Keep accurate records and interpret and communicate experimental results.
- Experience conducting laboratory bioassays in a research and development setting.
- Experience with insect bioassays.
- A background in automation, electronics, or robotics.
- Familiarity with laboratory equipment, automation, and high-throughput screening assays.
- Experience with bioassay development and implementation.
About the company
Corteva is a global agriculture technology company focused on helping farmers increase yields and protect crops. Its products include Pioneer seeds, crop protection solutions, and digital farming tools, plus gene-editing initiatives to support data-driven decisions. It differentiates itself as a pure-play agriculture company carved from DowDuPont, with a growing move into biologicals and a plan to spin into two independent companies (seeds and crop protection) by 2026. Its goal is to meet the food needs of a growing population with sustainable, profitable farming.
Company Size
10,001+
Company Stage
IPO
Headquarters
Indianapolis, Indiana
Founded
2019
Get referred to Corteva
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 operating EBITDA reached $3.70 billion on $6.38 billion sales.
- September 9, 2026 Globachem JV broadens the pipeline before Vylor separation.
- September 24, 2026 SEC effectiveness removed a key regulatory hurdle for the split.
What critics are saying
- FTC settlement on September 25, 2026 bans loyalty tactics for ten years.
- Latin America pricing fell 3% in first half 2026, showing intense generic pressure.
- Crop-protection growth depends on launches expected only in the early 2030s, risking stagnation.
What makes Corteva unique
- October 1, 2026 Vylor spin leaves Corteva a focused crop-protection pure play.
- Corteva combines global distribution, regulatory muscle, and post-patent chemistry at farm scale.
- Its Globachem JV extends late-stage formulation capacity across Europe and the Americas.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 0%Ascribe Bioscience launches Phytalix in Brazil with novel biochemical mode of action. Sep. 29, 2026 Ascribe Bioscience United States follow. US agricultural biotechnology company Ascribe Bioscience has launched Phytalix(R) in Brazil, marking the global commercial debut of the technology following regulatory approvals from Brazil's Ministry of Agriculture and Livestock (MAPA), National Health Surveillance Agency (Anvisa) and Brazilian Institute of Environment and Renewable Natural Resources (IBAMA). Founded in 2017, based upon research conducted at the Boyce Thompson Institute at Cornell University, Ascribe selected Brazil as the first commercial market for Phytalix, reflecting the country's role as a major testing and scale-up platform for biological and biochemical crop protection technologies. "The launch of Phytalix(R) brings Brazilian growers a powerful and sustainable new tool to strengthen plant defenses against major soybean and corn diseases. This revolutionary new molecule demonstrates that preventive crop protection, without harming the environment, can enhance fungicide performance within application programs that growers are already familiar with," said Gabriel Wilmoth, chief operating officer at Ascribe Bioscience. Soil science applied to crop immunity Unlike conventional chemical and microbial crop protection products that directly target pathogens, Phytalix is designed to act preventively by stimulating metabolic pathways and activating the plant's natural defense mechanisms. The Phytalix technology is based on an ascaroside, a compound associated with the soil microbiome that is synthesized under controlled laboratory conditions. According to Ascribe, the molecule primes the crop's immune system for a rapid response, while actual activation of defense barriers occur when the plant detects an invading pathogen. This mechanism is intended to avoid unnecessary energy expenditure by the plant, while enabling a faster defense response against disease pressure. Phytalix has also received its own resistance classification from the Fungicide Resistance Action Committee (FRAC), according to Ascribe. The classification places the technology in a new mode-of-action category and is intended to support resistance-management strategies and rotation of modes of action in crop protection programs. Biological technology with conventional operational profile A key feature of Phytalix is its operational stability, which the company says addresses some of the logistical constraints traditionally associated with biological crop protection products. Additionally, the Phytalix technology offers shelf stability and tolerance to temperature fluctuations, including heat and cold, as well as ultraviolet radiation. This allows it to be incorporated into existing farm application systems and machinery without requiring major operational changes. Phytalix was developed primarily for Brazil's soybean-corn production system and has also generated positive results in trials involving rice, coffee and cotton. Following five years of validation, Ascribe says Phytalix has been evaluated in more than 450 field trials across major agricultural regions, including Mato Grosso, Mato Grosso do Sul, Paraná, Rio Grande do Sul, São Paulo, Bahia, Goiás and Minas Gerais. According to Ascribe, the trials demonstrated Phytalix's efficacy against major soybean diseases, including brown spot, target spot and Asian soybean rust, as well as white spot and Bipolaris leaf spot in corn. Ascribe expects growers to generate additional commercial-scale productivity data during the 2026/27 season. "Phytalix(R) is the result of global science, independently validated by renowned researchers in Brazil and worldwide. Its versatility allows direct integration into resistance-management programs, reducing phytotoxicity and enhancing disease control with each application," said Edison Hidalgo, Ascribe's research and development manager in Brazil. Ascribe also said the molecule has been evaluated under a broad range of Brazilian climatic conditions and demonstrated a safety profile for growers, farm workers, consumers, pollinators, beneficial insects and soil biology. Global investment and Brazilian operation Ascribe Bioscience was founded by scientist Frank Schroeder and executive Jay Farmer. Ascribe recently raised US$12 million in investment, led by Corteva through Corteva Catalyst and Acre Venture Partners, with participation from Syngenta Group Ventures and other global agtech investors. To support its Brazilian commercial operation, Ascribe has established a local technical structure, with formulation and filling carried out in Brazil through strategic partners. Production of the active ingredient remains centralized in the United States. (Editing by Leonardo Gottems, reporter for AgroPages)
Corteva reaches $35 million settlement over alleged monopoly violations. Iowa is expected to receive about $2.4 million from a $35 million settlement with pesticide maker Corteva in a federal antitrust case. The Federal Trade Commission (FTC) and a bipartisan group of states, including Iowa, accused Corteva of using loyalty payments to encourage distributors to limit sales of competing products, including lower-cost generic pesticides. The agencies argued the practice restricted competition and artificially inflated chemical prices for farmers. Under the proposed settlement, Corteva would dismantle its existing loyalty program and face 10 years of restrictions on payments tied to distributors' purchases of its products over generic alternatives. Iowa Attorney General Brenna Bird, who joined the settlement on Iowa's behalf, says, "This is a great win for Iowa farmers, but also for all Iowans, Higher input prices for farmers growing our food mean higher prices at the grocery store. Iowa farmers and families deserve a marketplace without inflated prices." The settlement resolves the government's claims against Corteva, but a joint suit against fellow pesticide maker Syngenta is still pending. The agreement is separate from an $85 million proposed settlement of a class-action lawsuit involving more than 100,000 farmers. A link to the full settlement agreement is included with this story on its website.
Corteva's Drew Ratterman Receives MACA's Highest Award | Published on: Sep 21, 2026
Corteva and Belgium's Globachem N.V. announced a definitive agreement on 9 September to form a 50/50 joint venture developing crop protection products for Europe and the Americas. The deal comes ahead of Corteva's crop protection business spinning off as standalone company Vylor on 1 October. The venture builds on an existing relationship, combining Corteva's late-pipeline technology with Globachem's formulation expertise. New products aren't expected until the early 2030s, pending regulatory approval targeted for Q4 2026. Corteva's first-half 2026 net sales rose 4% to $11.28 billion, with operating EBITDA up 10% to $3.70 billion. However, crop protection segment pricing declined 3% in the first half due to competitive pressure in Latin America, despite a 2% volume increase.
Corteva (CTVA) bets on A Belgian partner for Crop Protection's next act. Published September 19, 2026 at 2:37 pm EDT On September 9, Corteva (NYSE:CTVA) and Belgium's Globachem N.V. announced a definitive agreement to form a 50/50 joint venture aimed at developing and commercializing new crop protection products for farmers in Europe and the Americas. The timing matters. Corteva's crop protection business is set to spin off as a standalone public company, Vylor, on October 1, and this deal signals what that company intends to look like once it is on its own. A pipeline built for independence. The joint venture builds on an existing multi-year relationship between the two companies, so this is not a cold start. Corteva brings late-pipeline and commercial-stage technology along with its own discovery and development capabilities, while Globachem contributes expertise in formulation and regulatory execution built as a private Belgian crop protection marketer. Corteva frames the venture as a way to combine those strengths and speed up delivery of more tailored crop protection solutions for core markets. The JV will operate independently, and any resulting products can be commercialized by either parent company, or both. The deal arrives against a backdrop of real financial momentum. In the first half of 2026, Corteva's net sales rose 4% to $11.28 billion, and operating EBITDA climbed 10% to $3.70 billion. Crop Protection itself posted a 2% volume increase in the first half, which the company attributed to demand for new products, and segment operating EBITDA rose 9% to $776 million even as pricing worked against it. That combination of rising volumes and expanding margins is the kind of foundation a soon-to-be standalone crop protection company would want heading into a major structural change. Growth with A pricing problem. Not every number told the same story. Corteva's second-quarter results, taken alone, were softer: net sales fell 1% year over year to $6.38 billion, organic sales declined 2%, and income from continuing operations dropped 12% to $1.22 billion, pulling GAAP earnings per share down 10% to $1.81. Operating EBITDA still grew in the quarter, but the gap between GAAP and non-GAAP performance is a reminder that reported profitability did not move in the same direction as the adjusted metrics investors tend to focus on. Pricing remains the sharper problem inside Crop Protection specifically. The segment's price declined 3% in the first half and 4% in the second quarter alone, both tied to competitive dynamics in Latin America, even as currency and volume gains offset some of the damage. The new joint venture does not fix that anytime soon. Corteva said the JV's new solutions are not expected to launch until the early 2030s, and the transaction itself still needs regulatory clearance before it can close, which the companies target for the fourth quarter of 2026. Meanwhile, Corteva is absorbing the costs and complexity of its own separation, including a $25 million headwind from separation-related timing already built into its full-year guidance. What the market is pricing in. Hedge fund ownership of Corteva climbed from 48 funds to 53 in the most recent quarter, which points to institutions adding rather than trimming positions. Short interest sits at just 3.05% of float, a level that suggests little organized skepticism is betting against the stock. The forward price-to-earnings ratio stands at 19.16, as of September 18, a multiple that assumes steady, not explosive, growth ahead. Rising fund interest paired with thin short positioning suggests the market is not bracing for a rocky separation, even with the pricing pressure still showing up in the numbers. The long runway ahead. Corteva is trying to do two hard things at once: split itself into two public companies and line up its next wave of crop protection products before the separation is even final. The Globachem venture gives the future standalone crop protection business a formulation partner and a longer pipeline, but the payoff sits years away in the early 2030s. Whether that is enough hinges on something closer to home: whether Crop Protection's recent volume gains can keep outrunning the price declines still showing up in Latin America. Investors clearly are not rattled yet, with fund ownership rising and short interest thin, but that patience will be tested well before the JV's products ever reach a farmer's field.